[1]CurrentPatentAssignee:SANOFI-US2006/69122,2006,A1Locationinpatent:Page/Pagecolumn6
[1]Patent:US2006/69122,2006,A1.Locationinpatent:Page/Pagecolumn7
[1]Crawford,JasonB.;Chen,Gang;Gauthier,David;Wilson,Trevor;Carpenter,Bryon;Baird,IanR.;McEachern,Ernie;Kaller,Alan;Harwig,Curtis;Atsma,Bem;Skerlj,RenatoT.;Bridger,GaryJ.[OrganicProcessResearchandDevelopment,2008,vol.12,#5,p.823-830]
[1]CurrentPatentAssignee:X4PHARMACEUTICALSINC-US10548889,2020,B1Locationinpatent:Page/Pagecolumn76;82
Title: The molecular pharmacology of AMD11070: an orally bioavailable CXCR4 HIV entry inhibitor.
Journal: Biochemical pharmacology 20120215
Title: Combination of drug therapy in acute lymphoblastic leukemia with a CXCR4 antagonist.
Journal: Leukemia 20110801
Title: Design of novel CXCR4 antagonists that are potent inhibitors of T-tropic (X4) HIV-1 replication.
Journal: Bioorganic & medicinal chemistry letters 20110301
Title: HIV-1 tropism.
Journal: Protein & cell 20100601
Title: Synthesis and SAR of novel isoquinoline CXCR4 antagonists with potent anti-HIV activity.
Journal: Bioorganic & medicinal chemistry letters 20100515
Title: Discovery of novel small molecule orally bioavailable C-X-C chemokine receptor 4 antagonists that are potent inhibitors of T-tropic (X4) HIV-1 replication.
Journal: Journal of medicinal chemistry 20100422
Title: Amine substituted N-(1H-benzimidazol-2ylmethyl)-5,6,7,8-tetrahydro-8-quinolinamines as CXCR4 antagonists with potent activity against HIV-1.
Journal: Bioorganic & medicinal chemistry letters 20090901
Title: Comparison of the potential multiple binding modes of bicyclam, monocylam, and noncyclam small-molecule CXC chemokine receptor 4 inhibitors.
Journal: Molecular pharmacology 20081201
Title: Pharmacokinetic effect of AMD070, an Oral CXCR4 antagonist, on CYP3A4 and CYP2D6 substrates midazolam and dextromethorphan in healthy volunteers.
Journal: Journal of acquired immune deficiency syndromes (1999) 20080415
Title: Multiple-dose escalation study of the safety, pharmacokinetics, and biologic activity of oral AMD070, a selective CXCR4 receptor inhibitor, in human subjects.
Journal: Antimicrobial agents and chemotherapy 20070701
Title: Emerging anti-HIV drugs.
Journal: Expert opinion on emerging drugs 20050501
Title: The appealing story of HIV entry inhibitors : from discovery of biological mechanisms to drug development.
Journal: Drugs 20050101
Title: Emerging drug targets for antiretroviral therapy.
Journal: Drugs 20050101
Title: HIV co-receptor drugs on the horizon.
Journal: GMHC treatment issues : the Gay Men's Health Crisis newsletter of experimental AIDS therapies 20040101
Title: Skerlj RT, et al. Discovery of novel small molecule orally bioavailable C-X-C chemokine receptor 4 antagonists that are potent inhibitors of T-tropic (X4) HIV-1 replication. J Med Chem. 2010 Apr 22;53(8):3376-88.
Title: Chow LN, et al. Impact of a CXCL12/CXCR4 Antagonist in Bleomycin (BLM) Induced Pulmonary Fibrosis and Carbon Tetrachloride (CCl4) Induced Hepatic Fibrosis in Mice. PLoS One. 2016 Mar 21;11(3):e0151765.
Title: Uchida D, et al. Effect of a novel orally bioavailable CXCR4 inhibitor, AMD070, on the metastasis of oral cancer cells. Oncol Rep. 2018 Jul;40(1):303-308.
